Belgian health platform Neuroventis accelerates internationalisation thanks to €1 million investment

Today Neuroventis, a digital platform for neurology, announces having raised €1 million. The new investors are CAREvolution and PMV, and the existing shareholders BlueHealth Innovation Fund and imec.istart reinvest. The startup is already supporting doctors and patients with neurological disorders in five European countries and will use the fresh funds to continue its internationalisation.

The startup states that in Belgium, one person in ten suffers an epileptic seizure in his or her lifetime and 20.2% of the population is confronted with a migraine attack. They go on to explain that the risk of death for people with epilepsy is three times higher than the national average and, in Belgium, more than 1,650,000 working days are lost each year due to migraine. Neuroventis was founded in 2017 to tackle these problems and give patients better control over their own health.

The Neuroventis platform is a CE-marked medical device that aims to help patients manage and register their neurological disorders and share their health data with their medical team. This is intended to allow the physician to have a better view of the patient’s evolution during the consultation and to base his therapeutic decisions on more objective data. The ultimate goal is to allow the physician to focus more on the patient during the consultation and to help the patient to better manage his health and prepare his consultations by means of an application, leading to patient empowerment.

“Thanks to a unique collaboration with medical specialists from different hospitals, such as the University Hospitals of Brussels and Leuven, as well as patient associations, we are helping to put the human being back at the heart of medical treatments by giving the patient the means to be a real actor in his or her own health on the one hand, and by helping specialists to establish a personalised approach per patient on the other”, explained Jonathan Schreiber, co-founder and CEO of Neuroventis.

“The lockdown due to COVID-19 has served as an important accelerator for an already existing growth of mHealth applications (mobile Health is the use of mobile devices, such as smartphones, in health management). Doctors and hospitals, as well as patients, increasingly see this as a unique opportunity to improve care”, according to Ludovic Ampe, co-founder of Neuroventis.

With this funding, Neuroventis aims to further internationalise and support more physicians and patients in different European countries. In addition, the startup will be active in trying to obtain reimbursement for applications as digital therapies. Finally, Neuroventis will also use part of the funds to extend its offer in neurology beyond epilepsy and headaches.

Currently, the Neuroventis platform supports more than 9,000 patients and around 150 healthcare providers.